The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?

Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted.PMID:34638308 | DOI:10.3390/cancers13194824

Source: Genomics Proteomics ... - October 13, 2021 Category: Genetics & Stem Cells Authors: Byeongsang Oh Frances Boyle Nick Pavlakis Stephen Clarke Thomas Eade George Hruby Gillian Lamoury Susan Carroll Marita Morgia Andrew Kneebone Mark Stevens Wen Liu Brian Corless Mark Molloy Benjamin Kong Towia Libermann David Rosenthal Michael Back Source Type: research